

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE {BOX}**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Cardisure flavoured 10 mg Tablets

**2. STATEMENT OF ACTIVE SUBSTANCES**

Each tablet contains:  
Pimobendan 10 mg

**3. PACKAGE SIZE**

20/50/100/250 tablets

**4. TARGET SPECIES**

Dogs.

**5. INDICATIONS**

**6. ROUTES OF ADMINISTRATION**

Oral use.

**7. WITHDRAWAL PERIODS**

**8. EXPIRY DATE**

Exp. {mm/yyyy}

**9. SPECIAL STORAGE PRECAUTIONS**

Do not store above 30 °C.  
Return any divided tablet to the opened blister and use within 3 days.

**10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”**

Read the package leaflet before use.

**11. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

**12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**13. NAME OF THE MARKETING AUTHORISATION HOLDER**

Eurovet Animal Health B.V.

**14. MARKETING AUTHORISATION NUMBERS**

Vm 16849/5016 (GB)

Vm 16849/3016 (NI)

**15. BATCH NUMBER**

Lot {number}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE  
PACKAGING UNITS {BLISTER}**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Cardisure flavoured

**2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES**

Pimobendan 10 mg/tablet

**3. BATCH NUMBER**

Lot {number}

**4. EXPIRY DATE**

Exp. {mm/yyyy}

## **PARTICULARS TO APPEAR ON THE PACKAGE LEAFLET:**

### **PACKAGE LEAFLET**

#### **1. Name of the veterinary medicinal product**

Cardisure flavoured 1.25/2.5/5/10 mg Tablets for Dogs

#### **2. Composition**

##### **Active substances:**

Pimobendan

1.25 mg: Each tablet contains 1.25 mg pimobendan

2.5 mg: Each tablet contains 2.5 mg pimobendan

5 mg: Each tablet contains 5 mg pimobendan

10 mg: Each tablet contains 10 mg pimobendan

Light brown round tablets, scored on one side and plain on the other side. The tablets can be divided into 2 (1.25 mg) or 4 (2.5 mg, 5 mg and 10 mg) equal parts.

#### **3. Target species**

Dogs.

#### **4. Indications for use**

For the treatment of canine congestive heart failure originating from valvular insufficiency (mitral and/or tricuspid regurgitation) or dilated cardiomyopathy.

#### **5. Contraindications**

Do not use in cases of hypertrophic cardiomyopathies or clinical conditions where an augmentation of cardiac output is not possible for functional or anatomical reasons (e.g. aortic stenosis).

#### **6. Special warnings**

##### Special warnings:

The veterinary medicinal product should be administered on an empty stomach at least one hour before meals, as absorption is reduced when given with feed.

##### Special precautions for safe use in the target species:

The veterinary medicinal product is flavoured. To avoid accidental ingestion the tablets should be stored out of reach of dogs.

An *in vitro* study in rat tissue demonstrated that pimobendan increased glucose-induced insulin release from pancreatic  $\beta$ -cells in a dose-dependent manner. If the veterinary medicinal product is administered to diabetic dogs, blood glucose levels should be carefully monitored.

As pimobendan is metabolised in the liver, particular care should be taken when administering the veterinary medicinal product to dogs with severe hepatic insufficiency.

Monitoring of cardiac function and morphology is recommended in animals treated with pimobendan. (See also section Adverse events).

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

Wash hands after use.

To the physician: Accidental ingestion, especially by a child, may lead to the occurrence of tachycardia, orthostatic hypotension, flushing of the face and headaches.

Pregnancy and lactation:

The safety of the veterinary medicinal product has not been established during pregnancy or lactation.

Use only according to the benefit-risk assessment by the responsible veterinarian.

Laboratory studies in rats and rabbits have not produced any evidence of teratogenic or foetotoxic effects. However, these studies have shown evidence of maternotoxic and embryotoxic effects at high doses and have also shown that pimobendan is excreted into milk.

Interaction with other medicinal products and other forms of interaction:

In pharmacological studies no interaction between the cardiac glycoside ouabain and pimobendan was detected. The pimobendan-induced increase in contractility of the heart is attenuated in the presence of the calcium antagonist verapamil and the  $\beta$ -antagonist propranolol.

Overdose:

In the case of overdose, a positive chronotropic effect and vomiting may occur. In this situation, the dosage should be reduced and appropriate symptomatic treatment should be initiated.

In prolonged exposure (6 months) of healthy beagle dogs at 3 and 5 times the recommended dose, mitral valve thickening and left ventricular hypertrophy were observed in some dogs.

## 7. Adverse events

Dogs:

Rare (1 to 10 animals / 10 000 animals treated):	Increased heart rate <sup>a,b</sup> , Increase in mitral valve regurgitation <sup>c</sup> Vomiting <sup>b</sup> , Diarrhoea <sup>d</sup> Anorexia (loss of appetite) <sup>d</sup> , Lethargy (lack of energy) <sup>d</sup>
Very rare (<1 animal / 10 000 animals treated, including isolated reports):	Mucosa petechiae (tiny blood spots under the skin) <sup>e</sup> , Subcutaneous haemorrhage (bleeding) <sup>e</sup>

<sup>a</sup>Moderate positive chronotropic effect.

<sup>b</sup>These effects are dose-dependent and may be avoided by reducing the dose in these cases.

<sup>c</sup>Has been observed during chronic pimobendan treatment in dogs with mitral valve disease.

<sup>d</sup>Transient.

<sup>e</sup>Although a relationship with pimobendan has not been clearly established, signs of effects on primary haemostasis may be observed during treatment. These signs disappear when the treatment is withdrawn.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or its local representative using the contact details at the end of this leaflet, or via your national reporting system at:

Website: <https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-medicine>

e-mail: [adverse.events@vmd.gov.uk](mailto:adverse.events@vmd.gov.uk)

## **8. Dosage for each species, routes and method of administration**

Oral use.

The tablets should be administered orally at a dose range of 0.2 mg to 0.6 mg pimobendan/kg body weight per day. The preferable daily dose is 0.5 mg pimobendan/kg body weight. The dose should be divided into two administrations (0.25 mg/kg body weight each), one half of the dose in the morning and the other half approximately 12 hours later. The maintenance dose should be individually adjusted according to the severity of the disease.

The veterinary medicinal product may be combined with a diuretic treatment, e.g. furosemide.

To break a tablet into two halves, place the tablet on an even surface with the scored side up, hold one half of the tablet and press down on the other half.



To break a double scored tablet into quarters, place the tablet on an even surface with the scored side up and apply pressure on the middle with your thumb.



Each dose should be given approximately one hour before feeding.

## **9. Advice on correct administration**

This veterinary medicinal product should be used only in dogs with cardiac insufficiency.

Do not exceed the recommended dosage.

To ensure a correct dosage, body weight should be determined as accurately as possible.

## **10. Withdrawal periods**

Not applicable.

## **11. Special storage precautions**

Keep out of the sight and reach of children.

Do not store above 30 °C.

Return any divided tablet to the opened blister and use within 3 days.

Do not use this veterinary medicinal product after the expiry date which is stated on the label after Exp. The expiry date refers to the last day of that month.

## **12. Special precautions for disposal**

Medicines should not be disposed of via wastewater.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

## **13. Classification of veterinary medicinal products**

Veterinary medicinal product subject to prescription.

## **14. MARKETING AUTHORISATION NUMBERS AND PACK SIZES**

Vm 16849/5018, Vm 16849/5017, Vm 16849/5016, Vm 16849/5015 (GB)

Vm 16849/3018, Vm 16849/3017, Vm 16849/3016, Vm 16849/3015 (NI)

### **Pack sizes:**

Aluminium – PVC/PE/PVDC blister:

10 tablets per blister: 2, 5, 10 or 25 blisters per carton.

Aluminium – Aluminium blister:

1.25 and 2.5 mg tablet: 10 tablets per blister: 2, 5, 10 or 25 blisters per carton.

5 and 10 mg tablet: 5 tablets per blister: 4, 10, 20 or 50 blisters per carton.

Not all pack sizes may be marketed.

**15. PID LINK (Do not print heading)**

*[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]*

Find more product information by searching for the 'Product Information Database' on [www.gov.uk](http://www.gov.uk).

**16. Contact details**

Marketing authorisation holder:

Eurovet Animal Health B.V.  
Handelsweg 25, 5531 AE Bladel  
The Netherlands

Manufacturer responsible for batch release:

Eurovet Animal Health B.V.  
Handelsweg 25, 5531 AE Bladel  
The Netherlands

Genera d.d.

Svetonedeljska cesta 2, Kalinovica  
10436 Rakov Potok, Croatia

Dales Pharmaceuticals Limited

Snaygill Industrial Estate, Keighley Road, Skipton  
North Yorkshire, BD23 2RW, United Kingdom

Local representatives and contact details to report suspected adverse events:

Dechra Veterinary Products Limited  
Sansaw Business Park  
Hadnall  
Shrewsbury  
Shropshire  
SY4 4AS  
United Kingdom  
Tel: +44 (0) 1939 211200

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

## 17. Other information

POM-V

When used in cases of valvular insufficiency in conjunction with furosemide, the veterinary medicinal product has been shown to improve the quality of life and extend life expectancy in treated dogs.

When used in a limited number of cases of dilated cardiomyopathy in conjunction with furosemide, enalapril and digoxin, the veterinary medicinal product has been shown to improve the quality of life and to extend life expectancy in treated dogs.

*Gavin Hall*

Approved: 06 January 2026